Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

By Melane Sampson Michael J. Roberts, PhD, CEO and Co-founder of Adaptin Bio Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering...

July 14, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026

Feature

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...

June 16, 2026

Feature

Healing the Hero rewiring trauma through neurolinguistic programming

The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...

June 9, 2026

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

Healing the Hero rewiring trauma through neurolinguistic programming

NEWS

Myricx to be acquired by Novartis for up to $1.5B

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Envoy reports improvement in speech perception in trial of cochlear implant

Valion advances integrated biodefense, immunology platform

VERAXA, Ardigen launch drug discovery collaboration

Virax signs immune profiling product supply deal with Fosun

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Just a few of the companies we’ve highlighted along the way

Subscribe